Gilles Millat1, Valérie Chanavat2, Robert Rousson3. 1. Laboratoire de Cardiogénétique Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France; NGS sequencing platform for molecular diagnosis, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Lyon, France. Electronic address: gilles.millat@chu-lyon.fr. 2. Laboratoire de Cardiogénétique Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France; NGS sequencing platform for molecular diagnosis, Hospices Civils de Lyon, Lyon, France. 3. Laboratoire de Cardiogénétique Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, France; NGS sequencing platform for molecular diagnosis, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Lyon, France.
Abstract
BACKGROUND: Hypertrophic and dilated cardiomyopathies are common genetic cardiac diseases. Due to large cohorts to investigate, large number of causative genes and high rate of private mutations, mutational screening must be performed using an extremely sensitive and specific detection method. METHODS: NGS workflow based on a custom AmpliSeq panel was designed for sequencing most prevalent cardiomyopathy-causing genes on the Ion PGM™ Sequencer. A cohort of 75 previously studied patients was screened to evaluate this strategy in terms of sensibility, specificity, practicability and cost. In silico analysis was performed using the NextGENe® software. RESULTS: Our AmpliSeq custom panel allowed us to efficiently explore 96% of targeted sequences. Using adjusted alignment settings, all genetic variants (57 substitutions, 34 indels) present in covered regions and previously detected by HRM/sequencing were readily identified except a 73-bp MYBPC3 deletion (analytical sensitivity: 98.9%). Uncovered targeted regions were further analysed by a HRM/sequencing strategy. Complete molecular investigation was performed faster and cheaper than with previously used mutation detection methods. CONCLUSION: Finally, these results suggested that our new NGS approach based on Ampliseq libraries and Ion PGM sequencing is a highly efficient, fast and cheap high-throughput mutation detection method that is ready to be deployed in clinical laboratories.
BACKGROUND:Hypertrophic and dilated cardiomyopathies are common genetic cardiac diseases. Due to large cohorts to investigate, large number of causative genes and high rate of private mutations, mutational screening must be performed using an extremely sensitive and specific detection method. METHODS: NGS workflow based on a custom AmpliSeq panel was designed for sequencing most prevalent cardiomyopathy-causing genes on the Ion PGM™ Sequencer. A cohort of 75 previously studied patients was screened to evaluate this strategy in terms of sensibility, specificity, practicability and cost. In silico analysis was performed using the NextGENe® software. RESULTS: Our AmpliSeq custom panel allowed us to efficiently explore 96% of targeted sequences. Using adjusted alignment settings, all genetic variants (57 substitutions, 34 indels) present in covered regions and previously detected by HRM/sequencing were readily identified except a 73-bp MYBPC3 deletion (analytical sensitivity: 98.9%). Uncovered targeted regions were further analysed by a HRM/sequencing strategy. Complete molecular investigation was performed faster and cheaper than with previously used mutation detection methods. CONCLUSION: Finally, these results suggested that our new NGS approach based on Ampliseq libraries and Ion PGM sequencing is a highly efficient, fast and cheap high-throughput mutation detection method that is ready to be deployed in clinical laboratories.
Authors: Allen S Ho; Angelica Ochoa; Gowtham Jayakumaran; Ahmet Zehir; Cristina Valero Mayor; Justin Tepe; Vladimir Makarov; Martin G Dalin; Jie He; Mark Bailey; Meagan Montesion; Jeffrey S Ross; Vincent A Miller; Lindsay Chan; Ian Ganly; Snjezana Dogan; Nora Katabi; Petros Tsipouras; Patrick Ha; Nishant Agrawal; David B Solit; P Andrew Futreal; Adel K El Naggar; Jorge S Reis-Filho; Britta Weigelt; Alan L Ho; Nikolaus Schultz; Timothy A Chan; Luc Gt Morris Journal: J Clin Invest Date: 2019-10-01 Impact factor: 14.808
Authors: Matthew B Lanktree; Bruce B Lanktree; Guillaume Paré; John S Waye; Bekim Sadikovic; Mark A Crowther Journal: Can J Gastroenterol Hepatol Date: 2015 Jan-Feb
Authors: C L Hertz; S L Christiansen; L Ferrero-Miliani; M Dahl; P E Weeke; G L Ottesen; R Frank-Hansen; H Bundgaard; N Morling Journal: Int J Legal Med Date: 2015-09-17 Impact factor: 2.686
Authors: Edelmann J; Dobosz T; Sobieszczanska M; Kawecka-Negrusz M; Dreßler J; Nastainczyk-Wulf M Journal: Int J Legal Med Date: 2016-09-09 Impact factor: 2.686
Authors: Carolyn Y Ho; Philippe Charron; Pascale Richard; Francesca Girolami; Karin Y Van Spaendonck-Zwarts; Yigal Pinto Journal: Cardiovasc Res Date: 2015-01-29 Impact factor: 10.787
Authors: Daniel L Polla; Maria T O Cardoso; Mayara C B Silva; Isabela C C Cardoso; Cristina T N Medina; Rosenelle Araujo; Camila C Fernandes; Alessandra M M Reis; Rosangela V de Andrade; Rinaldo W Pereira; Robert Pogue Journal: PLoS One Date: 2015-09-18 Impact factor: 3.240